Sorted By:

Relevance


America’s Biopharmaceutical Companies Launch Groundbreaking, Multi-Year Initiative Heralding New Era of Medicine

PhRMA  |  Press Release

#GoBoldly will be used across social media platforms to salute the sheer will and tenacity of patients and scientists fighting against disease every day.
https://www.phrma.org/press-release/america-s-biopharmaceutical-companies-launch-groundbreaking-multi-year-initiative-heralding-new-era-of-medicine

PhRMA Commends SCHIP Passage In Letter to House Speaker Nancy Pelosi

PhRMA  |  Press Release

In fact, reauthorization of SCHIP is just one of many ways that the health care system in American can work better for all Americans.
https://www.phrma.org/press-release/phrma-commends-schip-passage-in-letter-to-house-speaker-nancy-pelosi

I'm Not Average: Marina Is Living Well in Spite of Stomach Cancer

PhRMA  |  Blog Post

Technically Marina was too sick to qualify for the trial, a fact she and her physicians knew, but they also knew she had no other options.
http://catalyst.phrma.org/im-not-average-marina-is-living-well-in-spite-of-stomach-cancer

Health Care Access Concerns in the Media Spotlight

Access Better Coverage  |  From Our Network

Read more Insurers Increase Cost-Sharing Measures For Specialty Drugs FierceHealthPayerBy Dina Overland // December 3, 2014 Insurers are adopting more cost-sharing measures, especially coinsurance, to shift the costs of expensive specialty drugs onto consumers who purchase plans sold on health insurance exchanges, according to a new analysis from Avalere Health.
http://www.accessbettercoverage.org/articles/health-care-access-concerns-in-the-media-spotlight

The Story of Michelle Seng, Scientist, EMD Serono

PhRMA  |  Video

Watch "I Am Research. Progress. Hope." - The story of Michelle Seng, Scientist at EMD Serono. This initiative provides an opportunity for scientists working in drug discovery and development at America's biopharmaceutical companies to showcase their heroic and exciting work to younger generations...
https://www.phrma.org/video/the-story-of-michelle-seng-scientist-emd-serono

Celebrating diversity in the biopharmaceutical industry

PhRMA  |  Blog Post

As a member of the LGBT community myself, I see firsthand how our companies efforts to support inclusion are helping pave the way to new ideas and approaches to researching innovative medicines for patients.
http://catalyst.phrma.org/celebrating-diversity-in-the-biopharmaceutical-industry

I’m Not Average: Doreen’s Struggle with Cholesterol

PhRMA  |  Video

Despite Doreen’s best efforts, she struggles to control her cholesterol with statins and other cholesterol-lowering medicines.
https://www.phrma.org/video/i-m-not-average-doreen-s-struggle-with-cholesterol

World AIDS Day 2014: Transforming the Trajectory of Disease

PhRMA  |  Blog Post

We’ve seen unprecedented advances over the years to address this devastating disease, and today, we’re already seeing patients with access to medicines living close to normal life spans.
http://catalyst.phrma.org/world-aids-day-2014-transforming-the-trajectory-of-disease

Why Cross-Country Comparisons on Drug Prices are Misleading

PhRMA  |  Blog Post

Most cross-country comparisons focus solely on the list prices of medicines and exclude from calculations the steep discounts that are required in U.S. public programs such as Medicaid and the rebates negotiated by insurers and pharmacy benefit managers.
http://catalyst.phrma.org/why-cross-country-comparisons-on-drug-prices-are-misleading

Which 340B Entities Are Getting Most of the Savings?

PhRMA  |  Blog Post

The fact that DSH hospitals are the driving force behind the 340B program raises important questions about whether the program is serving its original goal of improving access to medicines for vulnerable or uninsured patients.
http://catalyst.phrma.org/which-340b-entities-are-getting-most-of-the-savings

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients

PhRMA  |  Blog Post

The shift in site of care from community-based physician practices to hospital-owned outpatient sites is leading to large revenue gains for the hospital and higher costs to the system.
http://catalyst.phrma.org/340b-spotlight-340b-hospitals-continue-to-benefit-from-consolidation-at-expense-of-patients

4 recommendations for ICER

PhRMA  |  Blog Post

In response to this call, PhRMA sent ICER a letter outlining several key steps that, if taken, would move ICER’s framework in a more methodologically rigorous, patient-centered direction.
http://catalyst.phrma.org/4-recommendations-for-icer

Antiretroviral Treatments and Ensuing Innovations Prevent Almost 900,000 Premature HIV/AIDS Deaths

PhRMA  |  Graphic

In the decades following the introduction of Highly Active Antiretroviral Therapy (HAART) for HIV/AIDS, we’ve seen tremendous progress against this devastating disease.
https://www.phrma.org/graphic/antiretroviral-treatments-and-ensuing-innovations-prevent-almost-900-000-premature-hiv/aids-deaths

Senior Director - Public Affairs

PhRMA  |  PhRMA Career

Experience in communicating across other cultures Ability to synthesize complex information for communication through various channels Experience in dealing with the media, ability to think on your feet and be diplomatic Service-oriented, able to work with many different groups and stakeholders Extensive experience in the use of social media, and the ability to leverage a variety of media tools Ability to inspire confidence within the organization and with external constituencies; Ability to travel approximately 15-20% of the time Preferred  Master’s or other advanced degree/studies in business or international affairs Who we are  The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.
https://www.phrma.org

Biopharmaceutical industry has made progress in cancer fight, continues work toward moonshot

PhRMA  |  Blog Post

 For example, we applaud Congress’ focus on biomedical innovation to accelerate new treatments and cures for patients as seen in the 21st Century Cures Act and in the Senate HELP Committee’s ongoing effort to spur medical innovation and look forward to continued work on this mission.
http://catalyst.phrma.org/biopharmaceutical-industry-has-made-progress-in-cancer-fight-continues-work-toward-moonshot

Medicare Monday: Call for repeal of IPAB intensifies

PhRMA  |  Blog Post

Congress must to listen to these calls to action and repeal IPAB before patients and the health care system are harmed.
http://catalyst.phrma.org/medicare-monday-call-for-repeal-of-ipab-intensifies

A Sea Change in Treating Heart Attacks

From Hope To Cures  |  From Our Network

“You will almost never see them.
http://www.fromhopetocures.org/a-sea-change-in-treating-heart-attacks

How Entities Qualify to Participate in 340B

Chartpack  |  From Our Network

The 340B designation applies to hospitals or clinics, which may claim steep discounts on outpatient drugs dispensed to all patients regardless of whether the patients are insured or uninsured.
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/how-entities-qualify-to-participate-in-340b

Setting the Story Straight on Rare Diseases

PhRMA  |  Blog Post

As the week that began with Rare Disease Day draws to a close, it's great to see that dialogue about the challenges associated with rare diseases continues.
http://catalyst.phrma.org/setting-the-story-straight-on-rare-diseases

Medicare Monday: Advancing treatments for osteoporosis with medicines in development

PhRMA  |  Blog Post

Take, for example, the fact that gaining Part D coverage was tied to an 8 percent decrease in hospital admissions.
http://catalyst.phrma.org/medicare-monday-advancing-treatments-for-osteoporosis-with-medicines-in-development

Who is pushing for price controls? The answer may surprise you

PhRMA  |  Blog Post

The Boston Globe, Boston Herald, and WBUR in Boston all recently reported that the health insurance industry is a driving force behind the Massachusetts legislation.
http://catalyst.phrma.org/who-is-pushing-for-price-controls-the-answer-may-surprise-you

PhRMA Statement on Dr. Scott Gottlieb’s Nomination to Lead the U.S. Food and Drug Administration

PhRMA  |  Press Release

Gottlieb in his new role and engaging with him and the Agency as they seek to modernize the drug discovery and review process and advance competition in the biopharmaceutical market.”
https://www.phrma.org/press-release/phrma-statement-on-dr-scott-gottlieb-s-nomination-to-lead-the-u-s-food-and-drug-administration

How Medicines Can Curb Health Care Costs

PhRMA  |  Video

Just one extra dollar spent on medicines for adherent patients with congestive heart failure, high blood pressure, diabetes and high cholesterol can generate $3 to $10 in savings on emergency room visits and inpatient hospitalizations.
https://www.phrma.org/video/how-medicines-can-curb-health-care-costs

Debunking Common Myths About Clinical Trials

PhRMA  |  Blog Post

FACT: Your doctor may not know about all available clinical trials that might benefit you.
http://catalyst.phrma.org/debunking-common-myths-about-clinical-trials

Ask About Adherence: Q&A on appointment-based medication synchronization

PhRMA  |  Blog Post

The cost-benefit of ABMS compared with standard pharmacy dispensing showed medical savings ranging from $1.25 to almost $37 per additional dollar spent depending on the medication class.
http://catalyst.phrma.org/ask-about-adherence-qa-on-appointment-based-medication-synchronization

You have reviewed the first 350 results out of 1196. Each page contains 25 results. You're on page 14.

prev 13 14 15 16 17 18 next